Drip-infusion of Remifentanil for RIH

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

559 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-05-01

Study Completion Date

2019-07-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The development of remifentanil-induced hyperalgesia (RIH) is an unpleasant experience for surgical patients. An alternative management, gradual withdrawal of remifentanil was effective in prevention of RIH. The investigators designed a simple modality to assess if under withdrawal of remifentanil and further drip-infusion of remifentanil immediately after extubation affected postoperative pain score, the requirement of rescue analgesics, and adverse effects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Opioid-induced Hyperalgesia After Remifentanil Infusion

NCT01702389

Hyperalgesia

COMPLETED PHASE4

Remifentanil and Hyperalgesia: Gradual Withdrawal Versus Immediate Discontinuation

NCT03110653

Anesthesia Pain

COMPLETED NA

Investigation of the Strategy of Preventing Post-operative Opioid-induced Hyperalgesia

NCT03812003

Opioid-Induced Disorders

UNKNOWN PHASE4

Comparing Efficacy of Intravenous Dexmedetomidine and Lidocaine on Postoperative Analgesia in Patients Undergoing Fracture Hip Surgery

NCT06865469

Fracture Hip Surgery

NOT_YET_RECRUITING PHASE3

Effect of Remifentanil on the Recovery Profile After Prolonged Head and Neck Surgery

NCT02416752

Pain Head and Neck Disorder

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In clinical practice, the gradual withdrawal of remifentanil during surgery is unsatisfied. Thus, the investigators conducted a simple modality in a single center retrospective cohort study to assess how under baseline gradual withdrawal of remifentanil and further drip infusion of remifentanil immediately after extubation affected postoperative pain score and use of analgesics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperalgesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

gradual withdrawal following by drip-infusion of remifentanil

In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated. Following by drip-infusion of remifentanil for 30 minutes was administered immediately after tracheal extubation.

remifentanil

Intervention Type DRUG

postoperative drip-infusion of remifentanil

gradual withdrawal of remifentanil

In the end of the surgery, gradual withdrawal of remifentanil was prescribed until the endotracheal tube was extubated.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

remifentanil

postoperative drip-infusion of remifentanil

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

drip-infusion

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of Anesthesiologists (ASA) score of I-III patients receiving total intravenous anesthesia

Exclusion Criteria

* The use of inhalation agents or propofol combined with inhalation anesthesia
* Pregnancy
* Previous substance abuse
* Known allergies to opioids, propofol or any drugs used in the study
* History of neuropsychiatric disorder
* Age \< 20 years or \> 80 years

Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No